ArticleHuman vaccines & immunotherapeutics2026

Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

Chunyan Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.